Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05108870 · ClinicalTrials.gov registry record · Phase 1

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

A Phase 1 study of Head and Neck Cancer and Human Papilloma Virus, sponsored by University of Chicago.

Recruiting
Registry status
Phase 1
Development phase
98
Enrollment target
1
Study location

NCT05108870 is a Phase 1 study of Head and Neck Cancer and Human Papilloma Virus that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 98 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05108870, a Phase 1 study of Head and Neck Cancer and Human Papilloma Virus, is actively recruiting participants, sponsored by University of Chicago.

RECRUITING
Registry status
Phase 1
Development phase
98 participants
Enrollment target
1
Study location

Study Summary

Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the study (induction) and if combining these medications can increase tumor shrinkage after therapy and reduce the amount of radiotherapy and chemotherapy that will later be needed. In addition, the study is looking at ways to reduce side effects overall using robotic surgery, chemotherapy and radiotherapy, or radiotherapy alone. Your participation in this research will last about 2 years. HB-201 and HB-202 are experimental (meaning the US Food and Drug Administration (FDA) has not approved these drugs), and therefore they can only be given in a research study.

Conditions Studied

Head and Neck Cancer Human Papilloma Virus Hpv HPV Positive Oropharyngeal Squamous Cell Carcinoma

Interventions

  • DRUG Carboplatin
  • DRUG Paclitaxel
  • DRUG HB-201
  • DRUG HB-202
  • PROCEDURE Transoral Robotic Surgery

Study Locations (1)

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2024-07-17
Est. Completion 2027-01-01
Phase Phase 1

Sponsor

University of Chicago

796 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05108870

The ClinicalTrials.gov registry entry for NCT05108870 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (62% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT05108870 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT05108870 about?

NCT05108870 is a clinical study titled "TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers". Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the study (induction) and if combining these medications can increase tumor sh...

What is the current status of trial NCT05108870?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2024-07-17. Estimated completion is 2027-01-01.

What conditions does trial NCT05108870 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Human Papilloma Virus, Hpv, HPV Positive Oropharyngeal Squamous Cell Carcinoma.

What interventions are being tested in trial NCT05108870?

The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), HB-201 (DRUG), HB-202 (DRUG), Transoral Robotic Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT05108870?

This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05108870 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Human Papilloma Virus

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.